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In Europe, gut decontamination (GD) is largely used in the prophylaxis of bacterial infections in  departments of 
oncohematology treating neutropenic patients, in particular those patients subject t o  profound (absolute neutrophil 
count (ANC) <100/mm3) and prolonged ( > I 0  days) neutropenia, such as patients undergoing bone marrow allografting 
or induction chemotherapy for acute leukemia. Initially, treatment was in  the form of non-absorbable antibiotics, but this 
has been partially superseded by quinolone-containing regimens, in particular in the centers participating in EORTC 
trials. In the last two EORTC trials comparing different regimens for the treatment of febrile neutropenia, 57-73% of the 
patients were receiving GD. A French epidemiologic study, performed prospectively and consecutively in  36 
oncohematology centers, has recently shown that 45% of febrile neutropenic patients receive digestive decontamination 
(DD) at the onset of their first febrile episode. 
The value of GD has been the subject of much controversy. Numerous trials, some of which were controlled, were 
performed in neutropenic patients in the 1980s’ prior to trials of GD in  intensive care units, but did not lead to  a consensus 
in the medical community of the value of GD. Moreover, GD is not, or is infrequently, used in  the USA. Apart from trials 
involving the quinolones, very few studies have been published during the last 10 years. Despite this, policies have not 
changed greatly in  the various centers. 
The CLIOH group has gathered the opinions of experts invited to  a multidisciplinary meeting that took place in Paris 
in  October 1996. The text that follows summarizes the reflections arising from this forum. It should be noted that this 
meeting was not designed to be a consensus conference, but rather to  re-examine the correlation between the data in  
the literature and actual clinical practice and to  highlight the main problems posed by DD in current oncohematology. 
The experts were separated into three working groups, each of which has drafted a report which appears in the text 
below. 
THE FUNDAMENTAL CONCEPTS OF GUT 
DECONTAMINATION 
The ecosystem 
The interrelationships between the intestinal bacterial 
flora and the host represent a complex ecosystem, 
which is specific for the host species and stable in time 
in a given individual. 
The intestinal flora is a line of defense which 
provides protection to the host against colonization by 
exogenous microorganisms. This phenomenon has 
been called ‘the barrier effect’ [l] or ‘resistance to 
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colonization’ [2]. The density of the bacterial 
population of the colon is of the order of 10” CFU/g 
of material. These bacteria comprise more than 400 
different species, with the majority being strict 
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Table 1 Ecosystem in normal adults (with dentition) 
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'Quantitative and qualitanve physiologic changes occur w t h  
teething 
bIncreased in dsease of the penodontium 
anaerobes. The interactions between different bacteria 
in the colon include: reciprocal promotion, total or 
partial growth inhibition, and exchange of information 
by in vivo transfer of DNA. These interactions 
maintain the stability of the ecosystem. The develop- 
ment of each bacterial strain within this ecosystem is 
not comparable to the situation in vitro in culture or in 
vivo in a monoxenous animal. 
Dominant populations are those bacterial strains 
with a population size that is 2 lo9 CFU/g of colonic 
material. In humans, these dominant populations are 
strict anaerobes. 
Other bacteria are always present but are main- 
tained as subdominant populations; such is the case for 
Enterobacteriaceae and enterococci. The resident flora 
of the digestive tube is an ensemble of the dominant 
and subdominant flora and its stability is remarkable. 
Other species may be transiently isolated (Pseudomonas 
aeruginosa, staphylococci, yeasts such as Candida). They 
are normally eliminated by the ecosystem. This resist- 
ance to colonization is regarded as a normal hnction 
of the intestinal flora, which thus plays a role in 
protecting the host. This hnction is mainly fulfilled by 
the dominant anaerobic populations (Table 1). 
Certain factors are capable of modifying this eco- 
system, most notably antibiotics, but also the diet, and 
changes in the gastric pH and in the bowel habitus. 
The modifications produced by antibiotics are 
dependent on: 
the concentration of active antibiotic in the 
intestinal lumen, whether this originates from the 
non-absorbed fraction of an orally administered 
drug or from bile elimination or excretion by the 
intestinal mucosa, regardless of the mode of 
administration; 
the activity of the antibiotic on the bacteria present 
in the intestinal lumen. 
Thus, the effect of an antibiotic on a bacterial strain can 
be divided into: 
a direct action on the strain; 
modification of the ecosystem, which itself affects 
the targeted strain. 
These interactions can be studied only in vivo. 
Experimental models using gnotobiotic (where the 
digestive flora is controlled) and axenic (germ-fi-ee) 
animals have allowed advances to be made in the study 
of resistance to colonization [3] .  
Aims of decontamination 
Neutropenic patients are at risk of bacteremia due to 
digestive tract organisms, The bacterial translocation 
and the passage across the intestinal mucosa of viable 
bacteria can lead to severe systemic infection in pro- 
foundly neutropenic patients (N< 100/mm3). This 
phenomenon has been observed with the Entero- 
bacteriaceae and Pseudomonas and was responsible for 
significant mortality up until the start of the 1980s 141. 
The aim of selective digestive decontamination 
(SDD) was to eradicate aerobic bacilli fi-om the 
intestinal lumen in order to eliminate the risk of 
bacteremia. So-called total digestive decontamination 
(TDD) has also been proposed and includes anaerobic 
organisms. A careful analysis of the literature shows that 
the concepts of SDD and TDD have not been clearly 
delineated. In both cases, the study criteria and the 
methods of control have generally been inadequate. 
Microbiological monitoring of decontamination 
AU antibiotic treatment gives rise to the risk of selecting 
potentially resistant pathogenic bacteria, which were 
present in the patient's flora or in the environment 
(resistant Enterobacteriaceae, Psetidomonas aeruginosa, 
enterococci, fungi, etc.) (Table 2). 
If SDD is not accompanied by microbiological 
monitoring, the following risks are incurred: 
primary failure if the patient is already colonized by 
potentially resistant pathogenic bacteria; 
intercurrent colonization, which occurs more 
rapidly and is more severe when the role of the 
ecosystem in host defense has been lost. 
This is true for all antibiotic treatment, regardless of its 
prophylactic or curative purpose and regardless of the 
route of administration, oral or parented. In practice, 
microbiological testing of feces involves evaluating the 
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Table 2 Effect of the main antibiotics on intestinal flora 
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'Variable effect, and hother cephalosporinase-producing Enterobacteriaceae. 'The majority of antibiotics predispose to colonization by fungi. 
EB, Enterobacteriaceae. R, resistant. 
potentially pathogenic groups of bacteria with use of 
appropriately selected media and measuring their 
sensitivity to the most important antibiotics used, either 
for prophylaxis or for treatment of active infection. 
Stool cultures must be performed before starting anti- 
biotic therapy and then twice weekly throughout the 
period of neutropenia (ANC < 5oo/nmi3). 
Which antibiotics? 
The ideal antibiotic for SDD would fulfill the following 
criteria: 
1. Active in the intestinal lumen against the Entero- 
bacteriaceae and Pxudomonar. 
3. Inactive against the anaerobes at the intestinal 
concentrations achieved. 
3. Low risk of resistance, due to the size of the targeted 
populations. 
4. Non-absorbable. 
5 .  Well tolerated. 
6. Satisfactory compliance. 
7. Reasonable cost. 
Three important points should be noted 
1. No oral antibiotic satisfactorily fulfills these criteria 
2. Most antibiotics given parenterally for treatment 
for selective decontamination. 
purposes have a decontaminating effect [5]. 
3.  All available antibiotics, whether given thera- 
peutically or prophylactically, have an ecological 
impact and exert selective pressures which expose 
the patient to resistant secondary infections. 
It can be concluded that: 
1. No prophylactic decontamination must be under- 
taken without appropriate bacteriological surveil- 
lance. 
2. This surveillance is highly recommended during 
therapeutic antibiotic administration in neutropenic 
patients. 
CLINICAL TRIALS OF GUT DECONTAMINATION 
The history of GD in hematology can be divided into 
three periods, which correspond with the evolution of 
the methods of antibacterial prophylaxis since the start 
of the 1970s: physical prevention of exposure to 
bacteria (protective isolation), followed by non- 
absorbable oral antibiotic therapy and then SDD. 
1970-80 The first clinical trials 
Following the initial epidemiologic studies on infec- 
tions in neutropenic patients and experimental studies 
in animal models, numerous teams have studied the 
efficacy of various GD regimens in order to decrease 
the frequency of infections during periods of aplasia, in 
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particular infections due to Gram-negative bacilli 
Six randomized studies including a sufficient 
number of patients, have been performed using non- 
absorbable GD regimens (gentamicin-vancomycin- 
nystatin or framycetin-colistin-nystatin), mainly in 
patients with acute leukemia [9-141. Five ofsix of these 
studies show that the GD significantly decreased the 
frequency of infections due to Gram-negative bacilli 
and infectious mortality during aplasia. The abrupt 
discontinuation of GD also seemed to favor the 
emergence of pathogenic organisms 191. However, the 
results of the different studies must be interpreted with 
caution, because: 
b-81. 
in the majority of these studies, GD was associated 
with protective isolation, which itself has been 
demonstrated to have a protective effect against 
colonization; 
both the clinical and microbiological efficacies are 
conditioned by the compliance to the treatment; 
in the studies analyzing subgroups of patients, the 
benefit of GD was found to be limited to patients 
who were profoundly neutropenic (N< 100/mm3) 
for at least 7 days; 
moreover, the majority of the studies highlighted the 
risk of the emergence of Gram-negative bacteria 
resistant to gentamicin. 
19804@ Selective decontamination, co-trimoxazole, and 
trials in bone marrow transplant patients 
The poor tolerance of non-absorbable GD and the 
problems of resistance, as well as the demonstration of 
the barrier effect of the anaerobic flora in animals, 
encouraged the study of the efficacy of absorbable or 
non-absorbable SDD regimens [ 151. 
Five randomized clinical trials, using different non- 
absorbable SDD regimens compared with no GD, 
showed a significant decrease in infections due to 
Gram-negative bacilli [8,12,16-181. 
The use of co-trimoxazole, although it was 
administered at doses varying by a factor of 1-4 in the 
various studies [19-211, was also of value in the 
prevention of infectious episodes in patients with a 
profound and lasting neutropenia, regardless of the 
organisms involved and even in the absence of a 
protected environment. However, its use for this 
indication was abandoned due to the rapid and frequent 
emergence of resistant mutants and to the significant 
delay in the recovery from aplasia in the groups of 
patients who received co-trimoxazole [22-241. 
The trials performed in bone marrow transplant 
patients with so-called total non-absorbable GD regi- 
mens have confirmed the results of previous studies 
carried out in patients undergoing induction treatment 
for acute leukemia, namely, the prevention of septi- 
cemia during aplasia. No benefit on the overall survival 
could be demonstrated, probably due to the high 
mortality rate in such patients, linked to factors 
inherent to transplantation such as graft-versus-host 
disease (GVHD), toxicity or relapse. On the other 
hand, the preventive effect of GD on the incidence of 
GVHD has been reported by several authors, in, 
unfortunately, non-randomized studies [25,261, and the 
effect appeared to be linked to good anaerobic decon- 
tamination [27]. However, the role of GD in GVHD 
remains controversial [28]. 
Finally, there has been no recent evaluation of the 
benefit of non-absorbable SDD, whether or not 
associated with isolation measures, in the context of the 
new broad-spectrum antibiotics used empirically or 
therapeutically in hematology. 
198!i-96. Use of the fluoroquinolones 
Whether compared with co-trimoxazole, a placebo, or 
a control group, the different randomized studies have 
shown that fluoroquinolones reduce the frequency of 
Gram-negative infections in patients with aplasia 
[29-351, regardless of the mode of isolation. The 
compliance is better than that with non-absorbable GD 
regimens [36], but it must be noted that there is: 
a trend for an increased incidence of infections due 
to Gram-positive cocci, most notably streptococci 
an emergence of strains resistant to fluoroquinolones 
1371 ; 
in the colonization flora. 
In the various studies using fluoroquinolones, no 
benefit in terms of survival could be demonstrated. 
Critical interpretation of clinical studies 
The literature concerning studies on GD is all the more 
difficult to interpret since some studies have included 
absorbable antibiotics (co-trimoxazole or fluoro- 
quinolones) which have systemic activity, and therefore 
a potentially therapeutic effect, bringing into question 
the use of the term GD [38]. Also, clinical trials are 
difficult to compare, because the regimens of GD, 
isolation and empirical first-line antibiotic treatment 
are very variable. However, all the studies have shown 
a decrease in the incidence of Gram-negative infections 
in decontaminated patients, given that the compliance 
and the in vitro microbiological efficacy were adequate. 
DD, whether total or selective, has not been shown to 
be effective in terms of mortality. However, this may be 
due to the huge number of patients necessary in each 
arm (probably more than 1000) to demonstrate such a 
benefit. 
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Any GD regimen must be adapted to the patient’s 
flora and the microbiological history and be associated 
with fungal decontamination. It is imperative to 
include microbiological surveillance of the patient as 
part of the GD protocol. In fact, digestive colonization 
during GD surveillance is a clear risk factor for trans- 
location. Thus, colonization by any organism found in 
pure culture or in a large amount, in a patient receiving 
decontamination, must lead to a change in, or 
withdrawal of, the GD and must guide the choice of 
systemic empirical antibiotics in case of fever. Only 
patients profoundly neutropenic (ANC < 1 OO/mm3) 
for more than 7 days seem to benefit from non- 
absorbable total decontamination or co-trimoxazole. 
TDD must be performed in a protected environ- 
ment aimed at eliminating any source of exogenous 
bacteria (sterile food and strict isolation). The data in 
the literature do not indicate whether SDD is better 
than so-called TDD, or vice versa, with respect to 
clinical outcome. Also, the various trials do not indicate 
whether it is better to pursue or to stop D D  when the 
patient receives systemic antibiotic treatment during 
aplasia. 
THE RISKS OF GUT DECONTAMINATION WITH 
ANTIBIOTICS 
The risks of GD with antibiotics depend on the 
different techniques used but may be grouped into four 
broad categories: problems with treatment compliance, 
the emergence of Gram-positive bacteria, the selection 
of aerobic Gram-negative bacteria resistant to the 
agents used, and the emergence of yeasts which may 
lead to a systemic infection. 
Total gut decontamination 
Antibiotic prophylaxis with oral non-absorbable anti- 
biotics was first evaluated in order to differentiate its 
action fi-om that of protective isolation. The theoretical 
risk of such total decontamination, the rationale for 
which is weak and based on attempts in surgery at 
decreasing the incidence of postoperative infections, is 
colonization by resistant exogenous bacteria and yeasts. 
In this case, the removal of the resistance to coloniza- 
tion (the barrier effect) by TDD is an additional risk 
factor for the blood passage of bacteria eventually 
emerging. The majority of these risks have been 
demonstrated in experimental models. They justify 
routine microbiological testing of the feces. 
The usual combination is gentamicin-vancomycin 
and nystatin [39], but many variants have been pro- 
posed 139,411. Although numerous secondary digestive 
effects have been described, such as anorexia, nausea 
and diarrhea, the global compliance is of the order of 
80% 1.101. However, this compliance has not been 
systematically studied, which makes the efficacy of this 
method difficult to precisely assess [42]. Above all, the 
use of regimens including an aminoglycoside is accom- 
panied by the appearance of enterobacteria resistant to 
gentamicin, or even multiresistant [40]. Moreover, this 
method promotes the emergence of resistance in the 
fecal flora of patients, in particular with respect to 
Klebsielfa [43], and thereby contributed to the intro- 
duction of other decontamination regimens. 
Finally, the use of oral vancomycin, whose efficacy 
remains unproven, could encourage the selection of 
enterococci 1441, or even staphylococci 1451, resistant to 
glycopeptides: the studies in animals and in human 
volunteers have shown that vancomycin selected 
resistant enterococci in large quantities in the feces 
(109/g), and the first reports of vancomycin-resistant 
staphylococci have been published. 
The concept of selective gut decontamination 
The concept of SDD is based on the notion of 
‘resistance to colonization’ [46]. The benefit of co- 
trimoxazole was initially suggested by Hugues et al 1471 
in the prophylaxis of infections due to Pneumocystis 
carinii. However, the use of co-trimoxazole was accom- 
panied by the selection of resistant Gram-negative 
bacteria (six of nine in the co-trimoxazole group versus 
two of 20 in the control group in the study by Dekker 
et a1 [21]), and an increase in the colonization by Grani- 
negative bacteria [19] or by yeasts and bacteria resistant 
to co-trimoxazole [20]. 
Sometimes, a decrease in infections due to Gram- 
positive cocci was obtained, but the price was an 
increase in resistance to the antibiotic [48]. Colistin was 
then added to co-trimoxazole with the aim of limiting 
the emergence of resistance, with some success [41]. 
However, the development of sometimes severe allergic 
reactions, the effects on hematopoiesis leading to the 
prolongation of the neutropenia, the poor activity 
against Pseudomonas of co-trimoxazole, in addition to 
the problems of resistance [49], led to the progressive 
decrease in its utilization in SDD regimens and its 
replacement by fluoroquinolones [29]. 
The introduction of fluoroquinolones 
In hematology, the fluoroquinolones were introduced 
for SDD because of their broad spectrum, associated 
with excellent clinical tolerance, good digestive absorp- 
tion and the complete preservation of the flora of the 
anaerobic barrier [50]. Despite the undoubted effective- 
ness of this approach in the prevention of infections due 
to Gram-negative bacilli in neutropenic patients as 
compared to placebo [31], cotrimoxazole [33] and 
non-absorbable antibiotics [30], the major concern is 
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the high frequency of resistance to fluoroquinolones 
shown by Gram-negative aerobic bacteria isolated from 
clinical samples [30,34] when the use of these 
antibiotics is neither controlled nor surveyed. In some 
centers, where the fluoroquinolones have been used for 
several years for prophylaxis, there has been an increase 
in resistance to ciprofloxacin from 10% to 30% in 10 
years [51]. Other areas of concern are: 
the non-negligible risk of infections due to selected, 
resistant Gram-negative bacilli, such as Aeudomonus  
aeruginosa and Enterobacter cloacae [30]; 
the increased incidence of Gram-positive infections, 
in particular those due to coagulase negative 
staphylococci (CNS) and a-hemolytic streptococci 
[30,33,52], although contradictory data exist [31]; 
the risk of bacteremia due to hemolytic strepto- 
cocci, which has led to the addition of macrolides 
or penicillins, with encouraging preliminary results, 
which are nevertheless controversial [52]. 
In summary, the precise role of fluoroquinolones for 
SDD remains unclear. One must bear in mind the 
narrow spectrum of the antibacterial activity of the 
currently available quinolones, and the possible need to 
provide anti-Gram-positive cover with another anti- 
biotic, leading to the risk of selection of multiresistant 
bacteria. 
Emergence of fungi 
Antibacterial decontamination, regardless of the method 
used, carries the risk of colonization by fungi, as is the 
case with broad-spectrum antibiotic therapy. This 
justifies the inclusion of antifungals in decontaminating 
regimens [53]. Despite numerous studies, the effective- 
ness of oral prophylaxis with amphotericin B against 
infections due to Cundidu spp. remains to be proven. 
Fluconazole has broad activity against Candida,  
good compliance, low toxicity and excellent bio- 
availability. It decreases systemic infections due to 
Candida albicans in high-risk patients [54,55], but the 
risk of colonization and infection by strains with 
reduced sensitivity or by species which are naturally 
resistant, such as C. krusei, are limitations to its use. 
CONCLUSIONS 
Current issues in 1999 
DD, whether total or selective, has not been shown to 
be effective in terms of mortality. What criteria can be 
used to follow the response to such prophylactic treat- 
ment? What is required is randomized, double-blind, 
placebo-controlled studies, of sufficient power, with 
patients without fever or infection at enrollment, to 
evaluate treatment compliance and its effects on clinical 
outcome using the following judgment criteria: 
time to the first febrile episode; 
time to the first documented infection; 
time to start of the first antibiotic treatment; 
the number of days under antibiotics, and the cost 
and number of antibiotics used 
the number of infectious episodes documented 
clinically and microbiologically; 
the duration of hospitalization. 
Such studies should consider the problems of the emer- 
gence of resistance and of Gram-positive infections 
and should as a matter of urgency, investigate medico- 
economic indicators [41,56]. 
In conclusion, DD, in the original sense of the 
term, is perhaps an obsolete concept in hematology, 
due to the extensive use of powerful systemic and 
broad-spectrum antibiotics. Is there still any value to 
antibiotic prophylaxis when effective curative treat- 
ments are available and are, in clinical practice, used 
very early in the course of the disease? The results in 
the literature supporting the use of DD are in fact from 
an era when the available systemic antibiotics were less 
active against a certain number of Gram-negative 
bacteria. The current use of broad-spectrum systemic 
antibiotics, which can themselves affect the digestive 
flora [5], brings into question the expected benefit from 
DD in the form that it is currently used in hematology, 
whether it is selective or total DD. 
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